Coeptis Therapeutics Holdings Inc Share Price & Technical Analysis
COEP · $16.40
Healthcare / Biotechnology
$16.40
As of April 24, 2026, Coeptis Therapeutics Holdings, Inc. was acquired by Z Squared Inc., in a reverse merger transaction. Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellu…
Price chart
Seasonality
May has 2 positive and 1 negative years (last 5 years shown)
23% return in 2026, 17% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -3% | -14% | -3% | 44% | – | – | – | – | – | – | – | – | 23% |
| 25 | 130% | -14% | -6% | -10% | 6% | -18% | 34% | 28% | 35% | -12% | 21% | -25% | 169% |
| 24 | -26% | -2% | -50% | 2% | -16% | 9% | -14% | -9% | -10% | 11% | 3% | 34% | -68% |
| 23 | 2% | -12% | -13% | -15% | 62% | -21% | -21% | -13% | 13% | 7% | -5% | -34% | -50% |
| 22 | – | – | – | – | – | – | – | – | – | -28% | -72% | -17% | -116% |
Monthly return % by calendar month · historical pattern, not a forecast
Bullish · Strong · Strong
As of April 24, 2026, Coeptis Therapeutics Holdings, Inc. was acquired by Z Squared Inc., in a reverse merger transaction. Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company's product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$102.06M
P/E ratio
—
52W high
$21.41
52W low
$6.80
Volume
1,11,929
Beta
-0.43
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Coeptis Therapeutics Holdings Inc share price today?
- Coeptis Therapeutics Holdings Inc (COEP) last traded around $16.40 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does COEP have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for COEP. Download the app for real-time alerts.
- How can I analyze Coeptis Therapeutics Holdings Inc stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.